WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 21, 2026, as new trials continued enrolment and companies released positive clinical research data.
Eloxx Pharmaceuticals Inc. (ELOX)
Eloxx is a clinical-stage biopharmaceutical company focused on the production of small molecule drugs that target the ribosome to inhibit the translation of nonsense mutations and promote the production of functional proteins. Shares surged over 16% to reach a 52-week high of $23.40 on Monday.
For the second quarter of 2026, the company reported a net loss of $4.5 million, considerably higher than the $1.9 million from last year, as R&D expenses increased by over 200%.
Drug candidates currently in the pipeline include ZKN-013 for treating rare skin diseases such as recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB). ZKN-013 has been licensed to Almirall, which is carrying out a Phase 1 study on the drug. The compound Exlauren is also under evaluation for treating nonsense mutation Alport syndrome (NMAS) and nonsense mutation autosomal dominant polycystic kidney disease (NMADPKD).
argenX SE (ARGX)
argenX SE is a commercial-stage immunology company specialized in therapies for severe autoimmune diseases by pairing with academics through an Immunology Innovation Program (IIP). The company's stock rose to 52-week high of $1,058.69 per share on Friday.
The company markets VYVGART Hytrulo for the treatment of generalized myasthenia gravis (gMG), immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy (CIDP). In the recent Phase 3 ALKIVIA trial, positive results were reported for VYVGART in treating autoimmune myositis as the study met its primary endpoint.
Additionally, the company is also developing ARGX-112 for atopic dermatitis, and ARGX-115 as an immunotherapy against tumors.
Corcept Therapeutics Incorporated (CORT)
Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares climbed to a 52-week high of $123.44 on Friday.
Last month, the company released second quarter financial results, and highlighted a revenue growth to $256 million from $194 million in the previous year. Sales of the drug Korlym - used to treat hyperglycemia in patients with Cushing's syndrome - contributed a product revenue of $208 million.
The lead drug candidate of the company, Relacorilant, is being advanced to treat hypercortisolism in Cushing's syndrome. Relacorilant marketed as Lifyorli was approved for ovarian cancer, while Dazucorilant is being evaluated for the treatment of Amyotrophic Lateral Sclerosis (ALS), and Miricorilant for metabolic associated steatohepatitis (MASH).
Boundless Bio Inc. (BOLD)
Boundless Bio is a clinical-stage oncology company advancing treatments for patients with oncogene-amplified tumors. Shares reached a 52-week high of $3.02 on Friday.
By targeting extrachromosomal DNA (ecDNA), the company is exploring the precise degradation of neoplastic cells without affecting healthy cells. Enrollment in a first-in human trial was initiated for BBI-940, a kinesin degrader which has demonstrated positive anti-cancer properties through in vitro studies.
The company saw a net loss of $13.6 million, compared to $15.8 million in the first quarter of this year.
Prelude Therapeutics Incorporated (PRLD)
Prelude Therapeutics is a clinical-stage precision oncology company engaged in formulating novel therapeutics to address rare neoplasms. On Friday, the company's stock reached a 52-week peak of $6.38.
The company has recorded progress in the development of their lead drug JAK2V617F, a mutant selective inhibitor used to treat myeloproliferative neoplasms (MPNs). JAK2V617F received an investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) in February, and a Phase 1 trial is continuing enrollment
Additionally, KAT6A, a developing drug to treat ER+ breast cancer, is due for an IND submission in the second half of 2026.
This Day In History:
On this day in 1826, anatomist Carl Gegenbaur was born. He was an early proponent of natural selection, and supported Darwin's theory of organic evolution by citing examples of homology in various animal organs. By identifying structural similarities based on common functionalities in anima organs, Gegenbaur and his contemporaries offered proof evolving species over centuries. In his text, Elements of Comparative Anatomy, he pointed out - 'The most important part of the business of comparative anatomy is to find indications of genetic connections in the organization of the animal body.'
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
